Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIGUEL ESTEBAN TREVINO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1760411029
CMS profile
33939
Location
CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$4,245.42

118 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,805.78 110
Travel and Lodging $1,439.64 8

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIGUEL ESTEBAN TREVINO

NPI 1760411029 · CMS profile ID 33939

Allopathic & Osteopathic Physicians / Internal Medicine

CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760411029?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIGUEL ESTEBAN TREVINO, NPI 1760411029, CMS profile ID 33939. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760411029?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MIGUEL ESTEBAN TREVINO, NPI 1760411029, CMS profile ID 33939. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760411029?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MIGUEL ESTEBAN TREVINO, NPI 1760411029, CMS profile ID 33939, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1760411029?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

118 matching records · $4,245.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 118 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–118 of 118.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.8702/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959490686 CMS
Lilly USA, LLC $18.5902/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918249815 CMS
Lilly USA, LLC $15.9202/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918204979 CMS
Novo Nordisk Inc $20.2002/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899153765 CMS
ABBVIE INC. $14.1302/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892549703 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $34.1902/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887406819 CMS
GlaxoSmithKline, LLC. $27.6702/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944883449 CMS
Janssen Pharmaceuticals, Inc $13.8202/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885912563 CMS
IMPEL PHARMACEUTICALS INC. $13.1902/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962324239 CMS
Biohaven Pharmaceutical Holding Company Ltd. $16.4802/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923757121 CMS
Lilly USA, LLC $14.5502/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918204977 CMS
ABBVIE INC. $19.0301/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892549701 CMS
AstraZeneca Pharmaceuticals LP $13.9701/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915757844 CMS
ABBVIE INC. $23.1801/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892549699 CMS
Novo Nordisk Inc $15.7401/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898586233 CMS
Biohaven Pharmaceutical Holding Company Ltd. $9.2501/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923757119 CMS
Amgen Inc. $18.7301/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939904311 CMS
Kowa Pharmaceuticals America, Inc. $11.7101/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 900380079 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,414.20 89
PY2020 $1,609.74 109
PY2021 $2,351.28 159
PY2022 $4,245.42 118
PY2023 $1,921.87 89
PY2024 $4,431.59 80
PY2025 $3,629.74 64

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,245.37 9
PY2025 Principal investigator $901,206.15 342
PY2024 Recipient $1,781.08 12
PY2024 Principal investigator $1,014,674.74 833
PY2023 Recipient $2,126.57 4
PY2023 Principal investigator $1,679,100.89 1,197
PY2022 Recipient $2,021.52 9
PY2022 Principal investigator $1,303,551.21 1,145
PY2021 Recipient $195.16 1
PY2021 Principal investigator $847,944.00 418
PY2020 Recipient $350.00 1
PY2020 Principal investigator $961,001.47 479
PY2019 Recipient $864.30 10
PY2019 Principal investigator $1,348,913.08 357

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

351 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202532470
Principal investigator 1 PFIZER INC. $617.50 12/31/2025 Non-covered Recipient Entity
Innovative Research of West Florida Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228749199
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298438
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298440
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298442
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298444
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298446
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298448
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298450
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298452
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298454
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298456
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298458
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298460
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298462
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298464
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298466
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298468
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298470
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298472
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298474
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298476
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298478
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298480
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298482
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298484
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298488
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298490
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298493
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298496
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298498
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298500
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298502
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298504
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298506
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298508
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298510
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298512
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298514
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298516
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298518
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298520
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298522
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298524
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298526
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298528
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298530
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298532
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298534
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298536
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298538
Principal investigator 1 Seqirus USA Inc $555.10 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298540
Principal investigator 1 Seqirus USA Inc $274.30 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298542
Principal investigator 1 Seqirus USA Inc $274.30 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298544
Principal investigator 1 Seqirus USA Inc $274.30 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298630
Principal investigator 1 Seqirus USA Inc $555.10 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298634
Principal investigator 1 Seqirus USA Inc $748.80 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298636
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298644
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298648
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298650
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298652
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298654
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298656
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298658
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298660
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298662
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298664
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298666
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298668
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298670
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298672
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298674
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298676
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298678
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298680
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298682
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298684
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298686
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298688
Principal investigator 1 Seqirus USA Inc $2,294.50 12/26/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298690
Principal investigator 1 Seqirus USA Inc $274.30 12/19/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298628
Principal investigator 1 Seqirus USA Inc $555.10 12/19/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298632
Principal investigator 1 Seqirus USA Inc $748.80 12/19/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298638
Principal investigator 1 Seqirus USA Inc $748.80 12/19/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298692
Principal investigator 1 Seqirus USA Inc $274.30 12/19/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298694
Principal investigator 1 Seqirus USA Inc $274.30 12/19/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298696
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,200.00 12/12/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) No dispute reported 06/30/2026 1185555137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $938.60 12/10/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510741
Principal investigator 1 ABBVIE INC. $3,394.30 12/05/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 12/04/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184269323
Principal investigator 1 PFIZER INC. $666.25 11/29/2025 Non-covered Recipient Entity
Innovative Research of West Florida Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228728691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $85.80 11/07/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184259121
Principal investigator 1 ABBVIE INC. $728.00 11/06/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202523477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $194.00 11/06/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67.00 11/06/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.75 11/06/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $63.00 11/06/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510722
Principal investigator 1 Alnylam Pharmaceuticals Inc. $160.50 11/06/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510726
Principal investigator 1 Alnylam Pharmaceuticals Inc. $61.00 11/06/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510730
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.00 11/06/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $54.00 11/06/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510737
Principal investigator 1 ABBVIE INC. $16,357.90 11/05/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522727
Principal investigator 1 Janssen Research & Development, LLC $1,409.00 10/31/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210851
Principal investigator 1 PFIZER INC. $308.75 10/31/2025 Non-covered Recipient Entity
Innovative Research of West Florida Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228741248
Principal investigator 1 Seqirus USA Inc $4,274.00 10/31/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810539
Principal investigator 1 Seqirus USA Inc $1,174.50 10/31/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,724.20 10/22/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510744
Principal investigator 1 Seqirus USA Inc $1,880.00 10/22/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298642
Principal investigator 1 Seqirus USA Inc $6,575.00 10/22/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298646
Principal investigator 1 ABBVIE INC. $1,384.50 10/21/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202517619
Principal investigator 1 ABBVIE INC. $1,384.50 10/21/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202517627
Principal investigator 1 ABBVIE INC. $2,256.80 10/21/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202517629
Principal investigator 1 ABBVIE INC. $2,256.80 10/21/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202517631
Principal investigator 1 PFIZER INC. $308.75 10/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228719819
Principal investigator 1 GlaxoSmithKline, LLC. $168.65 10/14/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192167922
Principal investigator 1 ABBVIE INC. $15,382.90 10/09/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $928.97 10/03/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184244745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,976.00 10/03/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184244747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,693.00 10/03/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184244749
Principal investigator 1 GlaxoSmithKline, LLC. $1,005.30 10/02/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167933
Principal investigator 1 Janssen Research & Development, LLC $1,260.00 09/25/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210792
Principal investigator 1 PFIZER INC. $1,604.85 09/24/2025 Non-covered Recipient Entity
Innovative Research of West Florida Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228759070
Principal investigator 1 ABBVIE INC. $2,256.80 09/18/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202511530
Principal investigator 1 ABBVIE INC. $3,340.00 09/18/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202511532
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 09/17/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510536
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,739.00 09/17/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510654
Principal investigator 1 Janssen Research & Development, LLC $2,835.00 09/15/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210628
Principal investigator 1 Seqirus USA Inc $111.30 09/15/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298624
Principal investigator 1 Seqirus USA Inc $177.19 09/15/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298626
Principal investigator 1 Seqirus USA Inc $1,420.20 09/15/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185298640
Principal investigator 1 Alnylam Pharmaceuticals Inc. $303.00 09/12/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $388.00 09/12/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510646
Principal investigator 1 Alnylam Pharmaceuticals Inc. $144.00 09/12/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510650
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $928.97 09/12/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184236626
Principal investigator 1 Janssen Research & Development, LLC $2,755.00 09/11/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210890
Principal investigator 1 PFIZER INC. $3,379.03 09/09/2025 Non-covered Recipient Entity
Innovative Research of West Florida Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228752879
Principal investigator 1 ABBVIE INC. $23,076.30 09/04/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509592
Principal investigator 1 GlaxoSmithKline, LLC. $3,388.24 09/03/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192168657
Principal investigator 1 ABBVIE INC. $956.14 08/28/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202506507
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 08/28/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192164740
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 08/28/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192164750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $957.70 08/26/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184230409
Principal investigator 1 Janssen Research & Development, LLC $1,487.00 08/25/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210533
Principal investigator 1 ABBVIE INC. $2,030.60 08/20/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202505271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $150.00 08/20/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510531
Principal investigator 1 Janssen Research & Development, LLC $791.00 08/19/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210128
Principal investigator 1 Janssen Research & Development, LLC $205.00 08/19/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210746
Principal investigator 1 Janssen Research & Development, LLC $2,457.00 08/19/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210922
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,407.00 08/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510566
Principal investigator 1 Alnylam Pharmaceuticals Inc. $61.00 08/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510570
Principal investigator 1 Alnylam Pharmaceuticals Inc. $181.00 08/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $63.00 08/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510577
Principal investigator 1 Alnylam Pharmaceuticals Inc. $54.00 08/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510580
Principal investigator 1 Alnylam Pharmaceuticals Inc. $194.00 08/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $160.50 08/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510589
Principal investigator 1 Alnylam Pharmaceuticals Inc. $259.00 08/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510593
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67.00 08/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510598
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.00 08/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510603
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67.00 08/15/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510704
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $957.70 08/14/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184228355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $288.00 08/13/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510658
Principal investigator 1 ABBVIE INC. $17,134.00 08/06/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503507
Principal investigator 1 GlaxoSmithKline, LLC. $1,216.00 08/06/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167925
Principal investigator 1 GlaxoSmithKline, LLC. $4,461.20 08/04/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192164763
Principal investigator 1 Janssen Research & Development, LLC $1,998.00 07/31/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210201
Principal investigator 1 Janssen Research & Development, LLC $4,762.00 07/31/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210303
Principal investigator 1 Janssen Research & Development, LLC $2,009.00 07/31/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210457
Principal investigator 1 Janssen Research & Development, LLC $267.00 07/31/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210496
Principal investigator 1 Janssen Research & Development, LLC $1,750.00 07/31/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210658
Principal investigator 1 Janssen Research & Development, LLC $16,562.00 07/31/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,368.76 07/31/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184222876
Principal investigator 1 Janssen Research & Development, LLC $16,902.00 07/28/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210258
Principal investigator 1 SANOFI US SERVICES INC. $281.68 07/28/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226120446
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.50 07/25/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510607
Principal investigator 1 Alnylam Pharmaceuticals Inc. $194.00 07/25/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510612
Principal investigator 1 Alnylam Pharmaceuticals Inc. $53.50 07/25/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67.00 07/25/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510621
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67.00 07/25/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510699
Principal investigator 1 GlaxoSmithKline, LLC. $4,986.00 07/23/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $928.97 07/22/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184217849
Principal investigator 1 Seqirus USA Inc $1,000.00 07/18/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298622
Principal investigator 1 ABBVIE INC. $436.80 07/17/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202498660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,791.64 07/17/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184217164
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,476.25 07/16/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510528
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,730.15 07/14/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510637
Principal investigator 1 Janssen Research & Development, LLC $788.00 07/14/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210930
Principal investigator 1 SANOFI US SERVICES INC. $9,300.00 07/14/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226120434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,368.76 07/10/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184214422
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 07/07/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,001.00 07/07/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $675.00 07/07/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510633
Principal investigator 1 SANOFI US SERVICES INC. $300.00 07/07/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226120440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,334.46 07/04/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184212925
Principal investigator 1 ABBVIE INC. $14,612.00 07/02/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $63.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $181.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510685
Principal investigator 1 Alnylam Pharmaceuticals Inc. $61.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $350.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510799
Principal investigator 1 Alnylam Pharmaceuticals Inc. $516.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510804
Principal investigator 1 Alnylam Pharmaceuticals Inc. $61.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $181.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $54.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $194.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $160.50 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510822
Principal investigator 1 Alnylam Pharmaceuticals Inc. $259.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510826
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510830
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510834
Principal investigator 1 Alnylam Pharmaceuticals Inc. $63.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.50 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510842
Principal investigator 1 Alnylam Pharmaceuticals Inc. $53.50 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510846
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31,326.20 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510850
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510854
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510858
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510862
Principal investigator 1 Alnylam Pharmaceuticals Inc. $61.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510866
Principal investigator 1 Alnylam Pharmaceuticals Inc. $54.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510870
Principal investigator 1 Alnylam Pharmaceuticals Inc. $194.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510874
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510878
Principal investigator 1 Alnylam Pharmaceuticals Inc. $181.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510882
Principal investigator 1 Alnylam Pharmaceuticals Inc. $259.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510886
Principal investigator 1 Alnylam Pharmaceuticals Inc. $160.50 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510890
Principal investigator 1 Alnylam Pharmaceuticals Inc. $194.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510894
Principal investigator 1 Alnylam Pharmaceuticals Inc. $54.00 07/02/2025 Non-covered Recipient Entity
Innovative Research of West Florida
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510898
Principal investigator 1 Seqirus USA Inc $675.00 07/02/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298620
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 06/25/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,014.08 06/24/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184210698
Principal investigator 1 GlaxoSmithKline, LLC. $873.00 06/20/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192164758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,415.41 06/19/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184209251
Principal investigator 1 Janssen Research & Development, LLC $39,616.00 06/13/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210560
Principal investigator 1 ABBVIE INC. $1,644.50 06/12/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202491011
Principal investigator 1 ABBVIE INC. $2,953.60 06/12/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202491013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $957.70 06/12/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184206337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,404.14 06/05/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184204237
Principal investigator 1 ABBVIE INC. $35,971.00 06/03/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,368.76 05/28/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184198911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,368.76 05/22/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184197661
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,724.20 05/21/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510795
Principal investigator 1 GlaxoSmithKline, LLC. $2,511.90 05/21/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192164744
Principal investigator 1 Janssen Research & Development, LLC $2,403.00 05/20/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210090
Principal investigator 1 GlaxoSmithKline, LLC. $468.00 05/16/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,725.34 05/08/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184193773
Principal investigator 1 ABBVIE INC. $11,251.50 05/07/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483793
Principal investigator 1 ABBVIE INC. $2,075.00 04/30/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480645
Principal investigator 1 Janssen Research & Development, LLC $1,568.00 04/30/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210266
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,028.16 04/28/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184190741
Principal investigator 1 GlaxoSmithKline, LLC. $5,101.20 04/23/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167918
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,319.56 04/22/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184185269
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,450.40 04/18/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510786
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,896.95 04/18/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510791
Principal investigator 1 Janssen Research & Development, LLC $408.00 04/17/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175211020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,808.28 04/15/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184183386
Principal investigator 1 GlaxoSmithKline, LLC. $3,339.12 04/10/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192164772
Principal investigator 1 Janssen Research & Development, LLC $6,246.00 04/10/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210065
Principal investigator 1 Janssen Research & Development, LLC $267.00 04/10/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210769
Principal investigator 1 Seqirus USA Inc $870.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298546
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298548
Principal investigator 1 Seqirus USA Inc $870.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298550
Principal investigator 1 Seqirus USA Inc $870.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298552
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298554
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298556
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298558
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298560
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298562
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298564
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298566
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298568
Principal investigator 1 Seqirus USA Inc $870.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298570
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298572
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298574
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298576
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298578
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298580
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298582
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298584
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298586
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298588
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298590
Principal investigator 1 Seqirus USA Inc $870.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298592
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298594
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298596
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298598
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298600
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298602
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298604
Principal investigator 1 Seqirus USA Inc $415.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298606
Principal investigator 1 Seqirus USA Inc $870.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298608
Principal investigator 1 Seqirus USA Inc $870.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298610
Principal investigator 1 Seqirus USA Inc $870.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298612
Principal investigator 1 Seqirus USA Inc $870.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298614
Principal investigator 1 Seqirus USA Inc $870.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298616
Principal investigator 1 Seqirus USA Inc $870.00 04/09/2025 Non-covered Recipient Entity
Innovative Research Of West Florida
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185298618
Principal investigator 1 Janssen Research & Development, LLC $280.00 04/04/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210634
Principal investigator 1 ABBVIE INC. $6,643.00 04/03/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202474275
Principal investigator 1 GlaxoSmithKline, LLC. $14,737.80 04/02/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1192164201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $928.97 04/01/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184180746
Principal investigator 1 Janssen Research & Development, LLC $4,884.00 03/24/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210319
Principal investigator 1 Alnylam Pharmaceuticals Inc. $20.57 03/21/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510782
Recipient Regeneron Pharmaceuticals, Inc. $36.26 03/21/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184123562
Recipient Regeneron Pharmaceuticals, Inc. $123.92 03/21/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184123564
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $85.80 03/19/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184174478
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,030.00 03/14/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $150.00 03/12/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510768
Principal investigator 1 Alnylam Pharmaceuticals Inc. $600.00 03/12/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,574.26 03/11/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184170828
Principal investigator 1 ABBVIE INC. $14,202.50 03/07/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202461577
Principal investigator 1 GlaxoSmithKline, LLC. $3,339.12 03/07/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192167930
Recipient Regeneron Pharmaceuticals, Inc. $288.15 03/07/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184123552
Recipient Regeneron Pharmaceuticals, Inc. $66.99 03/07/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184123554
Recipient Regeneron Pharmaceuticals, Inc. $33.71 03/07/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184123556
Recipient Regeneron Pharmaceuticals, Inc. $64.99 03/07/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184123558
Recipient Regeneron Pharmaceuticals, Inc. $32.99 03/07/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184123560
Recipient Regeneron Pharmaceuticals, Inc. $149.99 03/06/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184123550
Principal investigator 1 PFIZER INC. $3,000.00 03/04/2025 Non-covered Recipient Entity
Innovative Research of West Florida Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228722882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $741.00 03/04/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184156676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $364.00 03/04/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184156678
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,388.41 03/03/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510780
Principal investigator 1 PFIZER INC. $10,065.00 03/01/2025 Non-covered Recipient Entity
Innovative Research of West Florida Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228782623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2025 Non-covered Recipient Entity
Innovative Research of West Florida, Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518655
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2025 Non-covered Recipient Entity
Innovative Research of West Florida, Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518659
Principal investigator 1 ABBVIE INC. $286.00 02/25/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202453768
Principal investigator 1 GlaxoSmithKline, LLC. $2,880.90 02/25/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192164767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $258.00 02/21/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510764
Principal investigator 1 Janssen Research & Development, LLC $10,240.00 02/18/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,703.22 02/18/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184154272
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 02/18/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184154274
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,838.00 02/18/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184154276
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,041.00 02/18/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184154278
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,000.00 02/18/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184154280
Principal investigator 1 ABBVIE INC. $614.16 02/13/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202451117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,653.00 02/12/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510749
Principal investigator 1 Genentech, Inc. $829.00 02/10/2025 Non-covered Recipient Entity
Innovative Research of West Florida, Inc.
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1211614817
Principal investigator 1 ABBVIE INC. $21,495.50 02/06/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202447577
Principal investigator 1 Janssen Research & Development, LLC $5,250.00 02/06/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210225
Principal investigator 1 Janssen Research & Development, LLC $3,458.00 02/06/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210867
Principal investigator 1 ABBVIE INC. $897.00 02/05/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202444521
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2025 Non-covered Recipient Entity
Innovative Research of West Florida, Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518647
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2025 Non-covered Recipient Entity
Innovative Research of West Florida, Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518650
Principal investigator 1 ABBVIE INC. $291.20 01/29/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202441796
Principal investigator 1 ABBVIE INC. $276.90 01/29/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202441800
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30,436.24 01/29/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185555131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 01/24/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510752
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,895.00 01/24/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510756
Principal investigator 1 Alnylam Pharmaceuticals Inc. $846.00 01/24/2025 Non-covered Recipient Entity
Innovative Research of West Florida
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215510759
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,634.90 01/24/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185555135
Principal investigator 1 GlaxoSmithKline, LLC. $8,643.60 01/24/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192164754
Recipient Regeneron Pharmaceuticals, Inc. $448.37 01/20/2025 Covered Recipient Physician A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184123548
Principal investigator 1 Janssen Research & Development, LLC $1,295.00 01/16/2025 Non-covered Recipient Entity
Elias Rsrch Associates, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175210739
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,766.43 01/15/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA INC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185555133
Principal investigator 1 PFIZER INC. $374.00 01/10/2025 Non-covered Recipient Entity
INNOVATIVE RESEARCH OF WEST FLORIDA
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228724628
Principal investigator 1 GlaxoSmithKline, LLC. $1,695.00 01/08/2025 Non-covered Recipient Entity
INNOVATIVE RES OF W FL INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167914